Advanced Biomed Inc.
ADVB Nasdaq Services-Medical Laboratories Financials FY2024–FY2026
Last close · Oct 23, 2026
$3.17
8.4%What Advanced Biomed Inc. does
No business description yet.
- Legal name
- Advanced Biomed Inc.
- Fiscal year ends
- June 30, 2026
- Latest annual report
- 10-K · Oct 13, 2026
- Accession · CIK
- 0001213900-26-109029
0001941029
Revenue and margins
Advanced Biomed Inc. had $0.1M of revenue in fiscal 2026.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was — in fiscal 2026, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Advanced Biomed Inc. returned — to shareholders in fiscal 2026. The diluted share count rose 22.1%.
Balance sheet
Cash, debt and the ratios that show how comfortably Advanced Biomed Inc. can carry it.
| Fiscal year end | FY24 | FY25 | FY26 |
|---|---|---|---|
| Cash and short-term investments | $2.6M | $0.0M | $0.4M |
| Current ratio | 1.1x | 1.2x | 9.3x |
| Quick ratio | 1.1x | 1.2x | 9.3x |
| Total assets | $4.5M | $22.9M | $13.8M |
| Total liabilities | $2.8M | $19.4M | $1.5M |
| Shareholders' equity | $1.7M | $3.5M | $12.3M |
| Net debt (− = net cash) | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY24 | FY25 | FY26 |
|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✓ |
| Cash from operations is positive | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✓ | ✓ |
| Cash from operations exceeds net income | ✓ | ✕ | ✕ |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | — | ✓ | ✓ |
| Share count didn't rise | — | ✓ | ✕ |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | — |
| F-score | — / 3 | — / 6 | — / 6 |
| Accruals ratio | −14.7% | 18.8% | 47.1% |
| Altman Z'' | — | −1.97 | 8.58 |
3 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY24 | FY25 | FY26 |
|---|---|---|---|
| Income statement | |||
| Revenue | — | — | $0.1M |
| Research and development | $0.9M | $0.9M | — |
| Operating income | — | −$1.1M | −$6.2M |
| Pretax income | −$2.8M | −$1.1M | −$6.3M |
| Income tax | — | — | −$0.0M |
| Net income | −$2.8M | −$3.3M | $6.7M |
| Diluted EPS | −$0.14 | −$3.18 | $5.33 |
| Diluted shares | 0.02B | 0.00B | 0.00B |
| Cash flow | |||
| Cash from operations | −$2.1M | −$5.8M | −$1.9M |
| Capital expenditure | $0.1M | $0.0M | — |
| Free cash flow | −$2.2M | −$5.9M | — |
| Depreciation and amortization | $0.4M | $0.3M | — |
| Stock-based compensation | — | — | $1.7M |
| Balance sheet | |||
| Cash and short-term investments | $2.6M | $0.0M | $0.4M |
| Current assets | $3.1M | $22.4M | $13.7M |
| Current liabilities | $2.7M | $19.2M | $1.5M |
| Property and equipment, net | $0.5M | $0.1M | — |
| Intangible assets | $0.1M | — | — |
| Total assets | $4.5M | $22.9M | $13.8M |
| Total liabilities | $2.8M | $19.4M | $1.5M |
| Shareholders' equity | $1.7M | $3.5M | $12.3M |
| Margins | |||
| Operating margin | — | — | −4,885.2% |
| Net margin | — | — | 5,232.8% |
| Returns | |||
| Return on capital employed | — | −30.0% | −50.8% |
| Return on equity | −167.3% | −126.8% | 84.8% |
| Return on assets | −62.4% | −23.9% | 36.5% |
| Return on tangible equity | −180.2% | −93.7% | 54.4% |
| Growth | |||
| Share count change | — | −94.9% | 22.1% |
| Financial health | |||
| Current ratio | 1.1x | 1.2x | 9.3x |
| Quick ratio | 1.1x | 1.2x | 9.3x |
| Capital allocation | |||
| Stock comp / revenue | — | — | 1,358.9% |
| Quality scores | |||
| Altman Z'' | — | −2.0 | 8.6 |
| Accruals ratio | −14.7% | 18.8% | 47.1% |
Source: SEC EDGAR XBRL filings (CIK 0001941029). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.